Informations générales (source: ClinicalTrials.gov)
Acute Bronchiolitis and Severity Markers: Interest in Protein CC16 (CC16)
Interventional
N/A
University Hospital, Clermont-Ferrand (Voir sur ClinicalTrials)
novembre 2015
janvier 2019
29 juin 2024
Acute bronchiolitis is a common viral infection in infants mainly due to RSV and
rhinovirus.
Biomarkers can be useful for predicting its severity. The serum CC16 is a marker of
epithelial aggression. Its rate increase during RSV bronchiolitis in infants less than 7
months. It could be an early predictive biomarker of the severity of acute bronchiolitis,
and secondarily for the development of asthma.
Two other markers of airway aggression seem to increase during acute bronchiolitis: serum
SP-D protein and serum soluble receptor sRAGE.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHU Clermont-Ferrand - 63003 - Clermont-Ferrand - France | Patrick LACARIN | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Infants under 1 year old hospitalized for acute bronchiolitis
- Infants under 1 year old hospitalized for acute bronchiolitis
- Broncho dysplasia
- Preterm under 34 weeks
- Cystic fibrosis
- Immune deficiency
- Suspicion of primary ciliary dyskinesia
- Congenital heart disease
- Acute renal failure